ReviewDrug design, development and therapy2025
Endoplasmic Reticulum-Targeting Natural Compounds: A Novel Frontier in Alleviating Liver Fibrosis.
Review in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver fibrosis, a reversible yet critical stage in chronic liver disease progression, poses a significant global health burden with limited therapeutic options. This review comprehensively explores the molecular mechanisms of endoplasmic reticulum (ER) stress and its dual role in both parenchymal and non-parenchymal cells during liver fibrosis, alongside the therapeutic potential of natural compounds that target ER stress to alleviate fibrosis. Emerging evidence underscores ER stress and oxidative stress as pivotal drivers of hepatic fibrogenesis, primarily through activating hepatic stellate cells (HSCs). We systematically summarize a wide array of natural compounds, from polyphenols to terpenoids, that demonstrate potent anti-fibrotic effects by either ameliorating maladaptive ER stress in hepatocytes or selectively inducing pro-apoptotic ER stress in activated HSCs. Despite their promise, the clinical translation of these compounds is hampered by poor bioavailability and non-specific targeting. We highlight the groundbreaking potential of biomimetic nano-delivery systems, such as cell membrane-camouflaged nanoparticles, to overcome these barriers, offering precise targeting and enhanced therapeutic efficacy. Finally, we discuss current challenges and future directions, advocating for interdisciplinary efforts to advance ER stress-targeting strategies from bench to bedside.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.